{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:41:27Z","timestamp":1790890887528,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jbspin.2016.10.012","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T04:45:21Z","timestamp":1480049121000},"page":"685-691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumab"],"prefix":"10.1016","volume":"84","author":[{"given":"Christopher","family":"Banse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-6120","authenticated-orcid":false,"given":"Helena","family":"Polena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Stidder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Khalil-Mgharbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Houivet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lequerr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Fardellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Le-Lo\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Philippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Vilgrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2016.10.012_bib0190","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/ard.2004.029199","article-title":"Prevalence of rheumatoid arthritis in France: 2001","volume":"64","author":"Guillemin","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0195","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","article-title":"High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors","volume":"44","author":"Del Rinc\u00f3n","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0200","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.20407","article-title":"Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody","volume":"51","author":"Gonzalez-Juanatey","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/art.33336","article-title":"Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor \u03b1-induced VE-cadherin cleavage","volume":"64","author":"Sidib\u00e9","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0210","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood.V97.6.1679","article-title":"Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability","volume":"97","author":"Corada","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0215","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/labinvest.2013.106","article-title":"Autoantibodies to vascular endothelial cadherin in humans: association with autoimmune diseases","volume":"93","author":"Bouillet","year":"2013","journal-title":"Lab Invest"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0220","doi-asserted-by":"crossref","first-page":"L1232","DOI":"10.1152\/ajplung.00109.2006","article-title":"TNF-alpha increases tyrosine phosphorylation of vascular endothelial cadherin and opens the paracellular pathway through fyn activation in human lung endothelia","volume":"291","author":"Angelini","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0225","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0230","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jbspin.2013.09.001","article-title":"Recommendations for using TNF\u03b1 antagonists and French clinical practice guidelines endorsed by the French national authority for health","volume":"80","author":"Go\u00ebb","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0235","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.10877","article-title":"Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis","volume":"48","author":"Szkudlarek","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0240","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"Van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0245","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0250","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1172\/JCI118377","article-title":"IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines","volume":"97","author":"Carvalho","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0255","first-page":"555","article-title":"Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials","volume":"20","author":"Tugwell","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0260","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/art.1780381108","article-title":"Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality of life measures\u2019 responsiveness to treatment in a randomized controlled trial","volume":"38","author":"Buchbinder","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0265","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jbspin.2014.05.002","article-title":"Recommendations of the French society for rheumatology for managing rheumatoid arthritis","volume":"81","author":"Gaujoux-Viala","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0270","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/CIRCRESAHA.111.300483","article-title":"Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation","volume":"112","author":"Long","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0275","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2133.2003.05407.x","article-title":"Methotrexate inhibits proliferation and regulation of the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by cultured human umbilical vein endothelial cells","volume":"149","author":"Yamasaki","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0280","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/annrheumdis-2013-204986","article-title":"Pre-treatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial","volume":"74","author":"Hambardzumyan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0285","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/1529-0131(200012)43:12<2762::AID-ANR16>3.0.CO;2-#","article-title":"The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography","volume":"43","author":"Wakefield","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0290","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid Arthritis with concomitant therapy study group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0295","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British society for rheumatology biologics register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0300","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study","volume":"34","author":"Mancarella","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/art.23247","article-title":"Clinical remission and\/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study","volume":"59","author":"Burmester","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0310","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/rheumatology\/ken002","article-title":"Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish arthritis treatment group register","volume":"47","author":"Kristensen","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0315","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0320","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0325","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10067-012-2146-6","article-title":"A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers","volume":"32","author":"Pomirleanu","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0330","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1002\/art.20469","article-title":"The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept","volume":"50","author":"Criswell","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0335","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/art.11168","article-title":"Polymorphism at position \u2013308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis","volume":"48","author":"Mugnier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0340","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/annrheumdis-2011-200038","article-title":"In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial","volume":"71","author":"Rezaei","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0345","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.111171","article-title":"Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial","volume":"39","author":"Van der Heijde","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0350","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3899\/jrheum.121468","article-title":"Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a post-hoc analysis of the PREMIER study","volume":"41","author":"Keystone","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0355","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2152\/jmi.60.77","article-title":"Treatment responses and their predictors in patients with rheumatoid arthritis treated with biological agents","volume":"60","author":"Yuasa","year":"2013","journal-title":"J Med Investig"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0360","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/art.30596","article-title":"Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment","volume":"63","author":"Lal","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0365","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI25422","article-title":"Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis","volume":"116","author":"Kuhn","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jbspin.2016.10.012_bib0370","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1002\/art.27546","article-title":"Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis","volume":"62","author":"Vuilleumier","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16302111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16302111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T07:25:52Z","timestamp":1536218752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X16302111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1297319X16302111"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.012","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble vascular endothelial (VE) cadherin and autoantibodies to VE-cadherin in rheumatoid arthritis patients treated with etanercept or adalimumab","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}